Mer­ck’s HIV drug do­ravirine looks sol­id — though far less stel­lar than ri­vals — in 1st PhI­II

Mer­ck’s late-stage an­tivi­ral do­ravirine (MK-1439) came through in its first Phase III study, match­ing up nice­ly against J&J’s block­buster Prezista.

The non-nu­cle­o­side re­verse tran­scrip­tase in­hibitor com­pared close­ly to the ri­val ther­a­py in the non-in­fe­ri­or­i­ty test, adding a pos­i­tive sec­ondary end­point on low­er LDL lev­els among pa­tients. The drug used in a cock­tail rem­e­dy elim­i­nat­ed all signs of the virus among 83.8% (321/383) com­pared to 79.9% for Prezista (306/383).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.